Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

Shares of NASDAQ ZVRA opened at $8.11 on Wednesday. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a market capitalization of $432.88 million, a price-to ...

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th.The company reported ($0.69) earnings per share for the quarter, missing ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

Zevra Therapeutics (ZVRA – Research Report) received a Buy rating and a price target from Cantor Fitzgerald analyst Kristen Kluska today. The company’s shares closed yesterday at $8.24.

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...